ASIA Stock Overview
Asia Green Biotechnology Corp., an early stage international agro-technology company, focuses on the development, evaluation, testing, application, and supply of products derived from proprietary organic hybridization technology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Asia Green Biotechnology Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0 |
| 52 Week High | CA$0.08 |
| 52 Week Low | CA$0.005 |
| Beta | 1.28 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | n/a |
Recent News & Updates
Shareholder Returns
| ASIA | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | n/a | 6.8% | 0.8% |
| 1Y | n/a | -36.2% | 4.8% |
Return vs Industry: Insufficient data to determine how ASIA performed against the Canadian Biotechs industry.
Return vs Market: Insufficient data to determine how ASIA performed against the Canadian Market.
Price Volatility
| ASIA volatility | |
|---|---|
| ASIA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 12.5% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in CA Market | 18.0% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: ASIA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ASIA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | David Pinkman | www.asiagreenbiotechnology.com |
Asia Green Biotechnology Corp., an early stage international agro-technology company, focuses on the development, evaluation, testing, application, and supply of products derived from proprietary organic hybridization technology. The company focuses on planting, growing, and harvesting new and valuable strains of hemp and related crops. It has an agreement with Pathway Rx and PNW Biosciences Inc. for the clinical development and commercialization of the cannabis sativa varieties for prevention and treatment of COVID-19 and other infectious diseases.
Asia Green Biotechnology Corp. Fundamentals Summary
| ASIA fundamental statistics | |
|---|---|
| Market cap | CA$543.71k |
| Earnings (TTM) | -CA$134.83k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ASIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASIA income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$134.83k |
| Earnings | -CA$134.83k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0037 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -72.9% |
How did ASIA perform over the long term?
See historical performance and comparison